Literature DB >> 438282

Intermittent combination chemotherapy with chlorambucil and prednisone of low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification.

G Stolzenbach, M Garbrecht.   

Abstract

Fourty-three of 61 patients suffering from low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification were subjected to an intermittent combination chemotherapy with chlorambucil and prednisone. In 12 of 35 evaluable patients a complete remission, in 14 of 35 a partial remission could be achieved. The mean remission time of patients with a complete remission exceeds 16 months, that of patients with a partial remission amounts to more than 8 months. In 9 of 35 cases a remission could not be achieved. As 10 of the 12 patients in whom a complete remission could be obtained are alive, the median survival time in cases of complete remission cannot yet be determined. The hematological toxicity was very low, nausea and lack of appetite were observed in 9 of 35 patients. Three of 35 treated and evaluable patients died, viz., 1 patient with a centroblastic-centrocytic lymphoma and 1 patient with a chronic lymphocytic leukemia died from the sequelae of progression during the chemotherapy of second choice according to the COP regimen. The third patient with a centroblastic-centrocytic lymphoma died from the sequelae of an intrahepatic cholestatic icterus, also during the chemotherapy of second choice according to the COP regimen. In the last-mentioned case, autopsy also confirmed a continuous complete remission of the centroblastic-centrocytic lymphoma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438282     DOI: 10.1007/bf00406577

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  10 in total

1.  Recent trends in the treatment of non-Hodgkin's lymphomas.

Authors:  G Bonadonna; A Lattuada; A Banfi
Journal:  Eur J Cancer       Date:  1976-09       Impact factor: 9.162

2.  Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases.

Authors:  S E Jones; Z Fuks; M Bull; M E Kadin; R F Dorfman; H S Kaplan; S A Rosenberg; H Kim
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

3.  Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma.

Authors:  P S Schein; B A Chabner; G P Canellos; R C Young; C Berard; V T DeVita
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

4.  Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia.

Authors:  W H Knospe; V Loeb; C M Huguley
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

5.  Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma.

Authors:  J K Luce; J F Gamble; H E Wilson; R W Monto; B L Isaacs; R L Palmer; C A Coltman; J S Hewlett; E A Gehan; E Frei
Journal:  Cancer       Date:  1971-08       Impact factor: 6.860

6.  Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.

Authors:  C M Bagley; V T Devita; C W Berard; G P Canellos
Journal:  Ann Intern Med       Date:  1972-02       Impact factor: 25.391

7.  Clinical trials in the non-Hodgkin's lymphomata at Stanford University experimental design and preliminary results.

Authors:  S A Rosenberg; H S Kaplan
Journal:  Br J Cancer Suppl       Date:  1975-03

8.  [Clinical aspects of malignant non-Hodgkin's-lymphomas with reference to Kiel classification: centrocytic lymphoma, centroblastic-centrocytic lymphoma, lymphoblastic lymphoma, immunoblastic lymphoma].

Authors:  G Brittinger; H Bartels; K Bremer; E Dühmke; U Gunzer; E König; H Stein
Journal:  Hamatol Bluttransfus       Date:  1976

9.  Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma.

Authors:  B Hoogstraten; A H Owens; R E Lenhard; O J Glidewell; L A Leone; K B Olson; J B Harley; S R Townsend; S Miller; C L Spurr
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

10.  Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia.

Authors:  T Han; E Z Ezdinli; K Shimaoka; D V Desai
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.